Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

29.12 -0.58 (-1.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
 
Via Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
 
Via Benzinga
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
 
Via Benzinga
Recap: Ultragenyx Pharmaceutical Q4 Earnings
 
Via Benzinga
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
 
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
Via Benzinga
Topics Stocks
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
Via Benzinga
Topics Stocks
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. 
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Preview: Ultragenyx Pharmaceutical's Earnings
 
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate at Investor Conferences in March
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.